Not Yet RecruitingNot Applicable

Parathyroid Adenoma Detection With Rubidium-82 Imaging

Canada20 participantsStarted 2025-11

Plain-language summary

Assess the uptake of rubidium-82 in parathyroid adenomas.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Normocalcemic primary hyperparathyroidism
✕. Breastfeeding or pregnancy
✕. Claustrophobia or inability to undergo imaging logistics
✕. Any other history, condition, therapy, or uncontrolled intercurrent illness, which could in the opinion of the investigator affect compliance with study requirements or which would make the participant unsuitable for this study

Uptake pattern of rubidium-82 in parathyroid adenomas

Timeframe: 3 months

NCT IDNCT07099404

SponsorMatthieu Pelletier-Galarneau, MD MSc

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-09

Matthieu Pelletier-Galarneau, MD MSc